Madrigal Pharmaceuticals
MDGL
487.72
-8.73
-1.76%
Madrigal Pharmaceuticals
US · MDGL
#1355 by market cap
Listed 2016
487.72
-8.73
-1.76%
Live - 5344 symbols - heartbeat 253s ago
· 2026-10-08 07:10
Pre-market
498.89
+2.29%
After-hours
487.72
0.00%
- Market cap
- 11.27B
- P/E (TTM)i
- -34.86
- P/Bi
- 21.52
- EPSi
- -12.85
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on MDGL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 106.82% -0.33pp
- Institutions
- 500 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund54.62%
Hedge Fund41.38%
Private Company6.07%
Individual/Insider5.25%
Public Company2.58%
Government Pension Fund0.98%
Sovereign Wealth Fund0.94%
Insurance Company0.14%
Top holders as of 2026-06-30
Baker Bros. Advisors LP
9.28% · 2.14M sh
RTW Investments, LP
8.63% · 1.99M sh
Janus Henderson Group plc
8.38% · 1.94M sh
Avoro Capital Advisors LLC
7.94% · 1.83M sh
Paulson & Co. Inc.
5.80% · 1.34M sh
BlackRock
5.20% · 1.20M sh
Vanguard Capital Management, LLC
4.14% · 957.25K sh
Wellington Management Group
3.57% · 825.71K sh
Vanguard Portfolio Management, LLC
3.38% · 781.73K sh
SQN, LLC
2.84% · 655.54K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 21 sells
| Name | Role | Stake |
|---|---|---|
| Rebecca Taub | Founder, Chief Medical Officer, President of Research & Development and Director | 1.91% |
| Frederick Craves | Lead Independent Director | 1.59% |
| Paul Friedman | Director | 0.74% |
| William Sibold | Chief Executive Officer | 0.67% |
| Brian Lynch | General Counsel | 0.11% |
| Richard Levy | Independent Director | 0.10% |
| David Soergel | Chief Medical Officer | 0.04% |
| Robert Waltermire | Chief Pharmaceutical Development Officer | 0.03% |
| Raymond Cheong | Director | 0.02% |
| Julian Baker | Independent Chairperson | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-27 | Paul Friedman | Director | Intent to Sell (Form 144) | -50,000 | $516.56 |
| 2026-09-10 | William Sibold | Chief Executive Officer | Automatic Disposition | -5,221 | $533.09–546.38 |
| 2026-09-08 | William Sibold | Chief Executive Officer | Open Market Disposition | -6,362 | $527.88–542.55 |
| 2026-08-16 | Shannon Kelley | Chief Compliance Officer | Open Market Disposition | -664 | $514.97 |
| 2026-08-14 | John Reed | Director | Other Acquisition | +647 | -- |
| 2026-08-14 | John Reed | Director | Other Derivative Acquisition | +1,078 | $507.56 |
| 2026-07-19 | William Sibold | Chief Executive Officer | Derivative Exercise and Sale | -2,500 | $542.75–555.05 |
| 2026-07-16 | William Sibold | Chief Executive Officer | Derivative Exercise and Retained | +47,500 | -- |
| 2026-06-16 | Julian Baker | Independent Chairperson | Other Acquisition | +454 | -- |
| 2026-06-16 | Julian Baker | Independent Chairperson | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Jacqualyn Fouse | Director | Other Acquisition | +454 | -- |
| 2026-06-16 | Jacqualyn Fouse | Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Richard Levy | Independent Director | Other Acquisition | +454 | -- |
| 2026-06-16 | Richard Levy | Independent Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Rebecca Taub | Founder, Chief Medical Officer, President of Research & Development and Director | Other Acquisition | +454 | -- |
| 2026-06-16 | Rebecca Taub | Founder, Chief Medical Officer, President of Research & Development and Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | James Daly | Independent Director | Other Acquisition | +454 | -- |
| 2026-06-16 | James Daly | Independent Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Daniel Brennan | Director | Other Acquisition | +404 | -- |
| 2026-06-16 | Daniel Brennan | Director | Other Derivative Acquisition | +681 | $499.86 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:10:38 · For reference only, not investment advice and not tailored to your situation.